MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
1.690
+0.060
+3.68%
After Hours: 1.720 +0.03 +1.78% 19:42 02/06 EST
OPEN
1.660
PREV CLOSE
1.630
HIGH
1.750
LOW
1.630
VOLUME
3.96M
TURNOVER
--
52 WEEK HIGH
3.780
52 WEEK LOW
0.8621
MARKET CAP
379.79M
P/E (TTM)
-1.7226
1D
5D
1M
3M
1Y
5Y
1D
Allogene Therapeutics to Participate in Citi Virtual Oncology Leadership Summit and TD Cowen Health Care Conference
Reuters · 2d ago
Rapid Innovation is Reshaping Oncology: Stocks in Focus
NASDAQ · 2d ago
Allogene Therapeutics SVP and CTO Benjamin Machinas Beneski Reports Sale of Common Shares
Reuters · 3d ago
Allogene CFO Geoffrey M. Parker Reports Sale of Common Shares
Reuters · 3d ago
SVP and General Counsel Douglas Earl Martin Sells Common Shares of Allogene Therapeutics Inc
Reuters · 3d ago
Allogene Therapeutics SVP Finance Annie Yoshiyama Reports Disposal of Common Shares
Reuters · 3d ago
Allogene Therapeutics EVP of R&D Zachary Roberts Reports Disposal of Common Shares
Reuters · 3d ago
Weekly Report: what happened at ALLO last week (0126-0130)?
Weekly Report · 6d ago
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.